Results 271 to 280 of about 195,645 (350)

Targeted therapy for idiopathic pulmonary fibrosis: a bibliometric analysis of 2004-2024. [PDF]

Front Med (Lausanne)
Zhang X, Yuan Z, Shi X, Yang J.
europepmc   +1 more source

Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-analysis of Treatment Options and Outcomes, 1970 to Presen [PDF]

, 2003
Karen M Schoelles, Rhonda Estok, Linda R. Stone, Catherine Cella, Randall Kaye, Steven D. Nathan   +5 more
openalex   +1 more source

In Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates

Chemical Biology &Drug Design, Volume 106, Issue 1, July 2025.
Two compounds, A16 and A17, were active against multidrug‐resistant Mycobacterium tuberculosis isolates (PT‐12 and PT‐20), overcoming key resistance mutations in katG and rpoB, while cytotoxicity assays confirmed that they are non‐toxic. A17 exhibited the highest antituberculosis activity, with molecular docking suggesting enoyl‐[acyl‐carrier‐protein ...
Fernanda Rodrigues de Lima, Jéssika de Oliveira Viana, Aleff Cruz de Castro, Rodrigo Cristiano, Marcia Alberton Perelló, Alexia de Matos Czeczot, Cristiano Valim Bizarro, Pablo Machado, Luiz Augusto Basso, Claudio Gabriel Lima‐Junior, Valnês da Silva Rodrigues‐Junior, Karen Cacilda Weber   +11 more
wiley   +1 more source

Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective. [PDF]

Respir Res
Wang X, Xia X, Hou Y, Zhang H, Han W, Sun J, Li F.   +6 more
europepmc   +1 more source

Idiopathic pulmonary fibrosis: a treatable disease? [PDF]

, 2003
Ulrich Costabel
openalex   +1 more source

Anti‐neutrophil cytoplasmic antibodies associated interstitial pneumonia: A possible new clinical entity

European Journal of Clinical Investigation, Volume 55, Issue 7, July 2025.
In a study of 101 idiopathic interstitial pneumonia (IIP) and interstitial pneumonia with autoimmune features (IPAF) patients, 21 (20.8%) were ANCA‐positive. ANCA+ patients had higher rates of NSIP, bronchiectasis, arthralgias, and elevated CRP, with 43% of p‐ANCA+ patients progressing to systemic vasculitis (SV) within 12 months (OR 26.3, p < .0001 ...
Claudia Iannone, Maria Rosa Pellico, Antonella Caminati, Maurizio Zompatori, Lisa Tescaro, Francesca Luisi, Davide Elia, Maria Rosa Mirenda, Matteo Colleoni, Roberto Cassandro, Sergio Harari, Roberto Felice Caporali   +11 more
wiley   +1 more source

Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis. [PDF]

J Clin Med
Mullholand JB, Grossman CE, Perelas A.
europepmc   +1 more source

CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis [PDF]

, 2004
Takashi Inoue, Seitaro Fujishima, Eiji Ikeda, Osamu Yoshie, Nobuo Tsukamoto, Sadakazu Aiso, Naoki Aikawa, Atsushi Kubo, Kouji Matsushima, Kazuhiro Yamaguchi   +9 more
openalex   +1 more source

ILC2 Diversity, Location, and Function in Pulmonary Disease

Immunological Reviews, Volume 332, Issue 1, July 2025.
ABSTRACT Type‐2 inflammation is driven by the production of canonical type‐2 cytokines IL‐4, IL‐5, and IL‐13. Type‐2 cytokines promote mucus production, innate immune cell recruitment, and smooth muscle contractility in mucosal tissues. These hallmarks of type‐2 inflammation are important contributors to the weep‐and‐sweep responses observed in the ...
Mukesh Verma, Uryan I. Can, R. Lee Reinhardt   +2 more
wiley   +1 more source

Lung transplant bridging strategies in patients with idiopathic pulmonary fibrosis: An SRTR database analysis. [PDF]

JHLT Open
Suzuki Y, Deitz RL, Ryan J, Chan E, Furukawa M, Hage C, Sanchez PG.   +6 more
europepmc   +1 more source